Literature DB >> 9372952

Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression.

J S Qi1, V Desai-Yajnik, Y Yuan, H H Samuels.   

Abstract

Thyroid hormone receptor (T3R) is a member of the steroid hormone receptor gene family of nuclear hormone receptors. In most cells T3R activates gene expression only in the presence of its ligand, L-triiodothyronine (T3). However, in certain cell types (e.g., GH4C1 cells) expression of T3R leads to hormone-independent constitutive activation. This activation by unliganded T3R occurs with a variety of gene promoters and appears to be independent of the binding of T3R to specific thyroid hormone response elements (TREs). Previous studies indicate that this constitutive activation results from the titration of an inhibitor of transcription. Since the tumor suppresser p53 is capable of repressing a wide variety of gene promoters, we considered the possibility that the inhibitor is p53. Evidence to support this comes from studies indicating that expression of p53 blocks T3R-mediated constitutive activation in GH4C1 cells. In contrast with hormone-independent activation by T3R, p53 had little or no effect on T3-dependent stimulation which requires TREs. In addition, p53 mutants which oligomerize with wild-type p53 and interfere with its function also increase promoter activity. This enhancement is of similar magnitude to but is not additive with the stimulation mediated by unliganded T3R, suggesting that they target the same factor. Since p53 mutants are known to target wild-type p53 in the cell, this suggests that T3R also interacts with p53 in vivo and that endogenous levels of p53 act to suppress promoter activity. Evidence supporting both functional and physical interactions of T3R and p53 in the cell is presented. The DNA binding domain (DBD) of T3R is important in mediating constitutive activation, and the receptor DBD appears to functionally interact with the N terminus of p53 in the cell. In vitro binding studies indicate that the T3R DBD is important for interaction of T3R with p53 and that this interaction is reduced by T3. These findings are consistent with the in vivo studies indicating that p53 blocks constitutive activation but not ligand-dependent stimulation. These studies provide insight into mechanisms by which unliganded nuclear hormone receptors can modulate gene expression and may provide an explanation for the mechanism of action of the v-erbA oncoprotein, a retroviral homolog of chicken T3R alpha.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372952      PMCID: PMC232577          DOI: 10.1128/MCB.17.12.7195

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  103 in total

1.  The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing.

Authors:  A Baniahmad; X Leng; T P Burris; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

2.  Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein.

Authors:  P Sabbatini; S K Chiou; L Rao; E White
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

3.  Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor.

Authors:  J Casanova; E Helmer; S Selmi-Ruby; J S Qi; M Au-Fliegner; V Desai-Yajnik; N Koudinova; F Yarm; B M Raaka; H H Samuels
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

4.  DNA sequence specificity of the v-erb A oncoprotein/thyroid hormone receptor: role of the P-box and its interaction with more N-terminal determinants of DNA recognition.

Authors:  Z Smit-McBride; M L Privalsky
Journal:  Mol Endocrinol       Date:  1994-07

5.  Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

Authors:  J E Landers; D S Haines; J F Strauss; D L George
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

6.  Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  H Rhim; C O Echetebu; C H Herrmann; A P Rice
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-11

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

Authors:  J Lin; J Chen; B Elenbaas; A J Levine
Journal:  Genes Dev       Date:  1994-05-15       Impact factor: 11.361

9.  Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators.

Authors:  C M Chiang; R G Roeder
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

10.  The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation.

Authors:  J S Qi; V Desai-Yajnik; M E Greene; B M Raaka; H H Samuels
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

View more
  9 in total

1.  p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding.

Authors:  K C Lee; A J Crowe; M C Barton
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Regulation of the mdm2 oncogene by thyroid hormone receptor.

Authors:  J S Qi; Y Yuan; V Desai-Yajnik; H H Samuels
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

3.  PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors.

Authors:  M Mathur; P W Tucker; H H Samuels
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 4.  P53 mutations in thyroid carcinoma: tidings from an old foe.

Authors:  N R Farid
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

Review 5.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

6.  THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation.

Authors:  Akiko Katano-Toki; Tetsurou Satoh; Takuya Tomaru; Satoshi Yoshino; Takahiro Ishizuka; Sumiyasu Ishii; Atsushi Ozawa; Nobuyuki Shibusawa; Takafumi Tsuchiya; Tsugumichi Saito; Hiroyuki Shimizu; Koshi Hashimoto; Shuichi Okada; Masanobu Yamada; Masatomo Mori
Journal:  Mol Endocrinol       Date:  2013-03-22

Review 7.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

8.  Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.

Authors:  Laura Fozzatti; Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

9.  Genome-wide binding patterns of thyroid hormone receptor beta.

Authors:  Stephen Ayers; Michal Piotr Switnicki; Anusha Angajala; Jan Lammel; Anithachristy S Arumanayagam; Paul Webb
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.